報價延遲最少15分鐘:2025/07/16 13:38 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.49 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.28/-0.84
|
|
企業價值
141.77M
|
| 資產負債 |
|
每股賬面淨值
0.60
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
96.74M
|
|
每股收益
0.96
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/16 13:38 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |
